Biohit to promote stomach awareness - Gastro Treviso in June 29-30, 2013

        Print
| Source: Biohit Oyj
multilang-release

Biohit Oyj June 4, 2013 at 3:30 P.M. local time (EET)

Finnish healthcare company Biohit participates in Gastro Treviso, aim of which is to build public awareness of stomach health. Several parties shall cooperate in increasing public awareness of the health of the stomach in the event held Treviso, Italy in June.

The event is accompanied by international experts and local stakeholders such as hospitals, general practitioners, pharmacies and entrepreneurs. Common theme of the participants is the prevention of stomach problems, and aim to raise awareness about serious things in a positive and accessible way.

Gastro Treviso is organized in connection with Biohit's annual distributor meeting and Healthy Stomach Initiative Organization’s meeting.

CEO Semi Korpela, Biohit Oyj: ”This event brings together  both; the treating party as well as the ones to be treated. The meeting has great settings to spread the good news about our ground-breaking products to a wide range of general public and professionals.”

Professor Francesco Di Mario: ”GastroPanel has important role in early detection in stomach diseases with high mortality. Biohit provides not only early diagnosis with GastroPanel but also solution by offering the unique Acetium product to prevent carcinogenic acetaldehyde in stomach. We warmly welcome Biohit to join this healthy festival.”

More information can be found at www.gastrotreviso.it (in Italian)

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohithealthcare.com
 

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group 1 human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com


Healthy Stomach Initiative

The Healthy Stomach (HSI) Initiative is a non-profit-organization, which intends to promote research and create public awareness for preventing the development of gastric diseases, gastric symptoms and maintain stomach health.www.hsinitiative.org


Additional information about the GastroPanel examination:

Biohit Oyj has developed the GastroPanel biomarker tests, a unique blood sample examination for the screening and diagnosis of Helicobacter pylori infection and damage or dysfunction of the mucous membrane (atrophic gastritis) of the stomach. Unlike the H. pylori examinations still being used (13C urea breath test and stool antigen test), the GastroPanel tests reliably detect the H. pylori infection, the typically asymptomatic condition atrophic gastritis, and associated risks, including cancer.

The April 2012 Maastricht IV consensus report of the European Helicobacter Pylori Study Group recommends blood sample biomarker tests as a reliable method of diagnosis of diseases of the stomach mucosa and associated risk conditions. Researchers recommend biomarker tests for the diagnosis and follow-up of Helicobacter pylori infection and especially for atrophic gastritis that causes achlorhydric stomachs, as well as to the screening of asymptomatic patients. The report emphasises the fact that H. Pylori eradication therapy does not cure precancerous gastric conditions. This is why gastroscopy and biopsy examinations are recommended at regular intervals of 2-3 years for patients with moderately severe or severe atrophic gastritis. Without gastroscopy and biopsy examination, atrophic gastritis in the entire stomach (precancerous condition) and its location can only be diagnosed with a GastroPanel biomarker test.

The international Healthy Stomach Initiative group's 16 gastroenterology experts from 12 countries came to the same conclusions. Biomarker tests can be used to diagnose and screen atrophic gastritis and related risks in both asymptomatic patients and patients with abdominal discomfort (www.biohithealthcare.com: Investors/ Stock Exchange Releases: 17/02/2012 Biohit Oyj’s GastroPanel biomarker test recommended). According to the taskforce, GastroPanel biomarker tests, unlike the Helicobacter pylori examination tests still in use, reliably diagnose the most significant risk conditions of the acid-free stomach (atrophic gastritis). With the help of the GastroPanel test, patients can be referred to appropriate further examinations, therapy and treatment. At the same time it is also possible to reliably diagnose patients who have a “healthy” stomach, i.e. patients who do not have H. pylori infection and/or atrophic gastritis.

 An IARC (WHO agency on cancer research) classification of October 2009 states that acetaldehyde in alcoholic beverages and naturally generated in alcohol is a group 1 carcinogen and is therefore as carcinogenic as H. pylori, asbestos, formaldehyde and benzene. GastroPanel biomarker tests reliably detect an anacidic stomach which is the major risk factor of gastric cancer. In addition, recent studies show that acetaldehyde generated in an anacidic stomach is a significant reason for gastric and oesophageal cancer risk associated with the condition. Microbes from the mouth can colonise an acid-free stomach and produce carcinogenic acetaldehyde from sugar and alcohol. According to gene studies this is one of the major risk factors of gastric and oesophageal cancer. The risk can be reduced with the help of another Finnish innovation - prescription-free Acetium capsules, which are taken during food and alcohol consumption, to bind (neutralise) carcinogenic acetaldehyde in the stomach.

Literature:
1. Malfertheiner P et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. http://gut.bmj.com on May 18, 2012. European H. pylori Study Group, ESPSG.
2. Agréus L et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47:136-47.
3. World Health Organisation WHO, 2009. www.iarc.fr/en/media-centre/pr/2009/pdfs/pr196_E.pdf.